Magnesium Sulfate for the Improvement of Cognition in Patients With Alzheimer Disease

Alzheimer Disease Clinical Trial

Official title: Magnesium Sulfate for the Improvement of Cognition in Patients With Alzheimer Disease

Status Not yet recruiting

Clinical Trial Summary

This study is to examine the possible effect of supplementing Magnesium sulfate on patients with Alzheimer Disease (AD) in controlling or reducing the amount of amyloid present in the brain, and increasing cognitive ability in individuals that have amyloid deposits.

Clinical Trial Description

Recent findings suggest magnesium may be effective in ameliorating symptoms in an Alzheimer's disease-like pathological progression by reducing Aβ-plaque, thus preventing synapse loss and memory decline in transgenic mice. Common forms include magnesium sulfate.

As a nutritional adjunct in hyperalimentation, the precise mechanism of action for magnesium is uncertain. Predominant deficiency effects are neurological, e.g., muscle irritability, clonic twitching and tremors. Hypocalcemia and hypokalemia often follow low serum levels of magnesium. While there are large stores of magnesium present intracellularly and in the bones of adults, these stores often are not mobilized sufficiently to maintain plasma levels. Parenteral magnesium therapy repairs the plasma deficit and causes deficiency symptoms and signs to cease.

To provide a comprehensive clinical evaluation of the effects of Magnesium sulfate in AD patients, this study is designed to assess the impact of magnesium sulfate on amyloid plaque to generate valuable data on clinical utility for the use of diagnostic algorithms and foundation for the development of possible treatment. ;

Related Conditions & MeSH terms

• Alzheimer Disease

• NCT number: NCT03038334
• Study type: Interventional
• Source: Metabolic Therapy Inc.
• Contact: Dewey C Brown II, PhD
• Phone: 2145174004
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 20, 2017
• Completion date: October 20, 2019